|Bid||4,440.00 x 6100|
|Ask||4,500.00 x 13000|
|Day's range||4,319.00 - 4,492.00|
|52-week range||3,996.00 - 5,520.00|
|PE ratio (TTM)||16.78|
|Earnings date||3 Feb 2016 - 8 Feb 2016|
|Dividend & yield||2.80 (4.78%)|
|1y target est||68.80|
The chief executive of AstraZeneca has said uncertainty over the regulatory regime post-Brexit meant the company would "wait to see" before taking some key decisions about further investment ...
Moody's Investors Service said on Friday it changed its outlook on AstraZeneca Plc's long-term debt rating to negative from stable, a day after the company's closely watched advanced lung cancer trial failed. Moody's said the change in outlook reflects the increased execution risk present in the company's pipeline and the negative results of the lung cancer trial. AstraZeneca's combination of two injectable immunotherapy drugs failed to help patients as hoped in a closely watched advanced lung cancer trial, triggering the biggest ever daily fall in its shares on Thursday.
Rating Action: Moody's changes outlook on AstraZenaca's A3 rating to negative; affirms ratings. Global Credit Research- 28 Jul 2017. London, 28 July 2017-- Moody's Investors Service has today changed to ...